Effects of Sunitinib Malate on Growth of Human Bladder Transitional Cell Line T24 In Vitro
Jin Wen1, Han-zhong Li1, *, Zhi-gang Ji1, Jing Jin2
1 Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; 2 Department of Pharmacy, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Jin Wen, Han-zhong Li, Zhi-gang Ji, Jing Jin. Effects of Sunitinib Malate on Growth of Human Bladder Transitional Cell Line T24 In Vitro[J].Chinese Medical Sciences Journal, 2015, 30(1): 51-55.
Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011; 4:43-58.
2.
Petrillo M, Scambia G, Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs 2012;21:451-72.
3.
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-24.
4.
Tran TA, Kinch L, Peña-Llopis S. Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1. Mol Cell Biol 2013; 33:3762-79.
5.
Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650-6.
6.
Wu CL, Ping SY, Yu CP, et al. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J Med Sci 2012; 28:194-203.
7.
Kim S, Ding W, Zhang L, et al. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: A review of clinical trials. Onco Targets Ther 2014; 12:719-28.
8.
Szarvas T, Jäger T, Droste F, et al. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 2009; 15:193-201.